Concepedia

Stuart Turner

ST

Statistics

Publications

22

Citations

1.4K

H-Index

17

Active since

2005

Affiliations

Novartis (United States)(Current)

Novartis (Switzerland)

Massachusetts General Hospital

University of California, Davis

BC Cancer Agency

Stuart Turner is an author at Novartis (United States) specializing in medicine, heart failure, and cardiology.

Publications per year

2005–2024

22

Publications

22

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

Hope S. Rugo, Florence Lerebours, Eva Ciruelos et al. · The Lancet Oncology · 2021 · 349 citations

, , +17

Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction

Thomas A. Gaziano, Gregg C. Fonarow, Brian Claggett et al. · JAMA Cardiology · 2016 · 154 citations · Full text

, , +17

Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction

Nancy Luo, Gregg C. Fonarow, Steven Lippmann et al. · JACC Heart Failure · 2017 · 132 citations

, , +11

Home-Time After Discharge Among Patients Hospitalized With Heart Failure

Stephen J. Greene, Emily C. O’Brien, Robert J. Mentz et al. · Journal of the American College of Cardiology · 2018 · 119 citations · Full text

, , +8

Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS)

Guillaume Canaud, Juan Carlos López‐Gutiérrez, Alan D. Irvine et al. · Genetics in Medicine · 2023 · 92 citations · Full text

, , +7

1–5 of 22